N-LIfT / LIfT BioSci - LARVOL DELTA

LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs (GlobeNewswire) - "LIfT BioSciences...today announced successful proof-of-concept production of its patented cancer killing alpha neutrophils from induced pluripotent stem cells (iPSCs)...The successful outcome observed using iPSCs will allow the Company to produce even more scalable and cost-effective allogeneic immuno-modulatory alpha neutrophils (IMANs) because iPSCs can be almost infinitely expanded (multiplied) to provide a truly off-the-shelf product that can be used in all cancer patients without an ongoing need for stem cell donors....The Company’s first-generation platform, N-LIfT, which is haemopoietic stem cell (HSC) derived, is already moving into the clinic for its allogeneic HSC derived IMAN product with trials planned to commence in H1 2024."

Clinical data • New trial • Oncology • Solid Tumor

LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours (GlobeNewswire) - "LIfT BioSciences...announces exciting preclinical data demonstrating that its Immunomodulatory Alpha Neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities that are commonly now sighted by medical professionals as being critical for potentially curing solid tumours in patients, learning from the experience of other cell therapies that have struggled to realise their potential in the clinic....The immune-modulation was demonstrated to successfully recruit the rest of the immune system and suppress a immunosuppressive tumour micro-environment (TME). IMANp stimulated the recruitment, activation, and proliferation of CD4, CD8, NK cells and patient tumour infiltrating lymphocytes and resulted in 2-3 fold increases in tumour cell killing."

Preclinical • Oncology • Solid Tumor

LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS (GlobeNewswire) - "LIfT BioSciences is pleased to announce that it’s lead investor, Starbloom Capital, has provided further investment into the Company to accelerate LIfT’s R&D plans and progress N-LIfT, the Company’s first-to-market anti-cancer innate cell therapy, (Neutrophil Only Leukocyte Infusion Therapy) into clinical development by Q1 2024, within 15 months after demonstrating strong preclinical results....The additional funds are being deployed to help tech transfer N-LIfT to Good Manufacturing Practice standards for use in patients as LIfT moves into clinical trials. N-LIfT works by effectively transferring the innate immunity that some exceptional people naturally have in their body from their stem cells to cancer patients. The treatment can potentially give cancer patients around 20 times the cancer killing ability they had been exhibiting themselves. N-LIfT can potentially overcome hurdles encountered by other cell therapies in the treatment of solid tumours..."

Financing • Oncology

LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models (GlobeNewswire) - "LIfT BioSciences today announced that its first-in-class cell therapy destroyed on average over 90% of the tumoroid in a PDX organoid across five of the most challenging to treat solid tumour types including bladder cancer, rectal cancer, colorectal cancer, gastric cancer and squamous cell non-small cell lung cancer. The N-LIfT results showed four days of potent cytotoxicity against a range of high unmet need tumour types, including those that were unresponsive to chemotherapy. The results announced today build upon findings announced in March 2022 which showed potent tumour cell killing with N-LIfT in a lung tumoroid model (SC-NSCLC), with significant superiority over current standards of care, Keytruda and Cisplatin."

Preclinical • Bladder Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Rectal Cancer • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer

LIfT BioSciences N-LIfT cell therapy shows complete and superior cell killing in solid tumour organoids compared to Keytruda (GlobeNewswire) - "LIfT BioSciences...announces that N-LIfT, its Neutrophil-based Leukocyte Infusion Therapy, showed potent tumour cell killing in a lung Tumouroid model (SC-NSCLC), with significant superiority over current standards of care, Keytruda and Cisplatin. Non-Small Cell Lung Cancer (NSCLC) kills more people than any other cancer and the Squamous Cell (SC) variant has poorest survival due to the ineffectiveness of current treatment options....The research was conducted in partnership with Champions Oncology in a non-small cell lung cancer (NSCLC) squamous cell Tumouroid and showed that N-LIfT completely destroyed the tumour to the point that it lost all structural integrity, which in-vivo would result in it disintegrating in the body. Furthermore, N-LIfT showed complete superiority to Keytruda, a gold-standard treatment for NSCLC, in Tumouroid reduction, as observed by fluorescent intensity...."

Preclinical • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor